Details for Patent: 9,198,882
✉ Email this page to a colleague
Which drugs does patent 9,198,882 protect, and when does it expire?
Patent 9,198,882 protects PROCYSBI and is included in two NDAs.
Protection for PROCYSBI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has twenty-nine patent family members in nineteen countries.
Summary for Patent: 9,198,882
| Title: | Enterically coated cysteamine, cystamine and derivatives thereof |
| Abstract: | The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects. |
| Inventor(s): | Dohil; Ranjan (San Diego, CA), Schneider; Jerry (La Jolla, CA) |
| Assignee: | The Regents of the University of California (Oakland, CA) |
| Application Number: | 14/752,383 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,198,882 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Delivery; |
Drugs Protected by US Patent 9,198,882
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Horizon | PROCYSBI | cysteamine bitartrate | CAPSULE, DELAYED RELEASE;ORAL | 203389-001 | Apr 30, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Horizon | PROCYSBI | cysteamine bitartrate | CAPSULE, DELAYED RELEASE;ORAL | 203389-002 | Apr 30, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Horizon | PROCYSBI | cysteamine bitartrate | GRANULE, DELAYED RELEASE;ORAL | 213491-001 | Feb 14, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Horizon | PROCYSBI | cysteamine bitartrate | GRANULE, DELAYED RELEASE;ORAL | 213491-002 | Feb 14, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,198,882
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1919458 | ⤷ Sign Up | C300649 | Netherlands | ⤷ Sign Up |
| European Patent Office | 1919458 | ⤷ Sign Up | CR 2014 00013 | Denmark | ⤷ Sign Up |
| European Patent Office | 1919458 | ⤷ Sign Up | 194 50001-2014 | Slovakia | ⤷ Sign Up |
| European Patent Office | 1919458 | ⤷ Sign Up | 19/2014 | Austria | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
